Siemens Healthineers (ETR:SHL) received a €36.50 ($42.44) target price from HSBC in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the stock. HSBC’s price objective points to a potential upside of 8.18% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. Credit Suisse Group set a €33.50 ($38.95) price target on shares of Siemens Healthineers and gave the stock a “neutral” rating in a report on Friday, April 27th. DZ Bank reissued a “neutral” rating on shares of Siemens Healthineers in a report on Thursday, April 5th. Independent Research set a €35.00 ($40.70) price target on shares of Siemens Healthineers and gave the stock a “neutral” rating in a report on Thursday. JPMorgan Chase & Co. set a €32.60 ($37.91) price target on shares of Siemens Healthineers and gave the stock a “neutral” rating in a report on Wednesday, April 25th. Finally, Royal Bank of Canada set a €34.00 ($39.53) price target on shares of Siemens Healthineers and gave the stock a “neutral” rating in a report on Wednesday, April 25th. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Siemens Healthineers has an average rating of “Buy” and a consensus price target of €35.23 ($40.96).

ETR SHL opened at €33.74 ($39.23) on Friday.

About Siemens Healthineers

Siemens Healthineers AG develops, manufactures, and distributes imaging, advanced therapies, and diagnostic products and services to healthcare providers worldwide. It operates in three operating segments: Imaging, Advanced Therapies, and Diagnostics. The Imaging segment provides diagnostic imaging and ultrasound products and services.

Analyst Recommendations for Siemens Healthineers (ETR:SHL)

Receive News & Ratings for Siemens Healthineers Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siemens Healthineers and related companies with MarketBeat.com's FREE daily email newsletter.